Benzodiazepines, Serum
Use
This test provides quantitative measurement of multiple benzodiazepine compounds in serum, aiding in clinical drug monitoring, toxicology assessment, and therapeutic evaluation of benzodiazepine use or exposure. It facilitates confirmation of benzodiazepine presence and levels to inform clinical decision‑making.
Special Instructions
Samples must be collected as serum (red‑top tube, no gel), frozen for transport, and strictly avoid serum separator tubes (SST). Processing occurs on specific days (Tuesdays, Thursdays, Saturdays) at set times. The assay was developed and analytically validated in‑house under CLIA regulations.
Limitations
The test has not been cleared or approved by the FDA; it is validated under CLIA. Quantitative values reflect analyte levels but may not directly correspond to dosage or timing due to metabolism and elimination dynamics. Use of serum may be limited compared to urine in certain contexts, and serum separator tubes (SST) are unacceptable.
Methodology
Mass Spectrometry
Biomarkers
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL (1 mL minimum)
Minimum Volume
1 mL
Container
red‑top tube (no gel)
Storage Instructions
Frozen for transport
Causes for Rejection
Serum separator tube (SST)
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 24 hours |
| Refrigerated | 72 hours |
| Frozen | 14 days |